These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32986666)

  • 1. Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging.
    Xia Y; Yassi N; Raniga P; Bourgeat P; Desmond P; Doecke J; Ames D; Laws SM; Fowler C; Rainey-Smith SR; Martins R; Maruff P; Villemagne VL; Masters CL; Rowe CC; Fripp J; Salvado O;
    J Alzheimers Dis; 2020; 78(1):321-334. PubMed ID: 32986666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease.
    Yassi N; Hilal S; Xia Y; Lim YY; Watson R; Kuijf H; Fowler C; Yates P; Maruff P; Martins R; Ames D; Chen C; Rowe CC; Villemagne VL; Salvado O; Desmond PM; Masters CL
    J Alzheimers Dis; 2020; 73(3):897-907. PubMed ID: 31884485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults.
    Schreiner SJ; Kirchner T; Narkhede A; Wyss M; Van Bergen JMG; Steininger SC; Gietl A; Leh SE; Treyer V; Buck A; Pruessmann KP; Nitsch RM; Hock C; Henning A; Brickman AM; Unschuld PG
    Neurobiol Aging; 2018 Mar; 63():152-161. PubMed ID: 29310864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study.
    Kim JW; Byun MS; Yi D; Lee JH; Ko K; Jeon SY; Sohn BK; Lee JY; Kim YK; Shin SA; Sohn CH; Lee DY;
    PLoS Med; 2020 Feb; 17(2):e1003022. PubMed ID: 32097439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
    Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
    JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.
    Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith S; Robertson J; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2018; 65(4):1313-1325. PubMed ID: 30149452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals.
    Lim YY; Williamson R; Laws SM; Villemagne VL; Bourgeat P; Fowler C; Rainey-Smith S; Salvado O; Martins RN; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2017; 58(4):1293-1302. PubMed ID: 28550258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
    Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
    Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease.
    Gaubert M; Lange C; Garnier-Crussard A; Köbe T; Bougacha S; Gonneaud J; de Flores R; Tomadesso C; Mézenge F; Landeau B; de la Sayette V; Chételat G; Wirth M
    Alzheimers Res Ther; 2021 Jan; 13(1):29. PubMed ID: 33461618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults.
    Hollands S; Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Harrington K; Porter T; Snyder P; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Rowe CC; Masters CL; Maruff P;
    J Alzheimers Dis; 2017; 57(2):411-422. PubMed ID: 28234254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.
    Rabin JS; Schultz AP; Hedden T; Viswanathan A; Marshall GA; Kilpatrick E; Klein H; Buckley RF; Yang HS; Properzi M; Rao V; Kirn DR; Papp KV; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
    JAMA Neurol; 2018 Sep; 75(9):1124-1131. PubMed ID: 29799986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.